Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C12H16N2 |
| Molecular Weight | 188.2688 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(N)CC1=CNC2=CC=CC=C12
InChI
InChIKey=ZXUMUPVQYAFTLF-UHFFFAOYSA-N
InChI=1S/C12H16N2/c1-2-10(13)7-9-8-14-12-6-4-3-5-11(9)12/h3-6,8,10,14H,2,7,13H2,1H3
ETRYPTAMINE (MONASE®), similar to the hallucinogenic tryptamines, is an inhibitor of monoamine oxidase, introduced for use as an antidepressant. It was withdrawn from the market due to problems with agranulocytosis and other side effects. However, it's activity is still under scientific investigation.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://patents.google.com/patent/US3296072 https://books.google.ru/books?id=l1DrqgobbcwC&pg=PA102&lpg=PA102&dq=Monase retrieved from Hallucinogens: A Forensic Drug Handbook: Richard R. Laing, Barry L. Beyerstein, Jay A. Siegel, p.102 https://www.ncbi.nlm.nih.gov/pubmed/13685431 https://www.ncbi.nlm.nih.gov/pubmed/13765760 |
Primary | Monase Approved UseDepression Launch Date1960 |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
8.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099943/ |
single, oral |
ETRYPTAMINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
50 mg 1 times / day multiple, oral Highest studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 61-93 years n = 5 Health Status: unhealthy Condition: depression Age Group: 61-93 years Sex: M+F Population Size: 5 Sources: |
Other AEs: Palpitation, Nervousness... Other AEs: Palpitation (3 patients) Sources: Nervousness (3 patients) |
30 mg 1 times / day multiple, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, 61-93 years n = 24 Health Status: unhealthy Condition: depression Age Group: 61-93 years Sex: M+F Population Size: 24 Sources: |
Other AEs: Palpitation, Nervousness... Other AEs: Palpitation (4 patients) Sources: Nervousness (4 patients) |
700 mg single, oral Overdose |
unknown n = 1 |
Other AEs: Malignant hyperthermia... Other AEs: Malignant hyperthermia (grade 5, 1 patient) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Nervousness | 3 patients | 50 mg 1 times / day multiple, oral Highest studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 61-93 years n = 5 Health Status: unhealthy Condition: depression Age Group: 61-93 years Sex: M+F Population Size: 5 Sources: |
| Palpitation | 3 patients | 50 mg 1 times / day multiple, oral Highest studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 61-93 years n = 5 Health Status: unhealthy Condition: depression Age Group: 61-93 years Sex: M+F Population Size: 5 Sources: |
| Nervousness | 4 patients | 30 mg 1 times / day multiple, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, 61-93 years n = 24 Health Status: unhealthy Condition: depression Age Group: 61-93 years Sex: M+F Population Size: 24 Sources: |
| Palpitation | 4 patients | 30 mg 1 times / day multiple, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, 61-93 years n = 24 Health Status: unhealthy Condition: depression Age Group: 61-93 years Sex: M+F Population Size: 24 Sources: |
| Malignant hyperthermia | grade 5, 1 patient | 700 mg single, oral Overdose |
unknown n = 1 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
TiHKAL
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
||
|
DEA NO. |
7249
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
||
|
WIKIPEDIA |
Designer-drugs-Monase
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
||
|
NCI_THESAURUS |
C667
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1117
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
PRIMARY | |||
|
DB01546
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
PRIMARY | |||
|
100000082116
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
PRIMARY | |||
|
SUB07347MIG
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL1619758
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
PRIMARY | |||
|
1276
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
PRIMARY | |||
|
alpha-Ethyltryptamine
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
PRIMARY | α-Ethyltryptamine (αET, AET), also known as etryptamine (INN, BAN, USAN), is a psychedelic, stimulant, and entactogenic drug of the tryptamine class. It was originally developed and marketed as an antidepressant under the brand name Monase by Upjohn in the 1960s. αET is structurally and pharmacologically related to αMT, α-methyltryptamine, and it is believed[4] its central stimulant activity is probably not due to its activity as an MAOI, but appears to stem from its structural relationship to the indolic psychedelics. In contrast to αMT, αET is less stimulating and hallucinogenic, its effects resembling more those of entactogens like MDMA ("Ecstasy"). | ||
|
C72772
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
PRIMARY | |||
|
m727
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
C038034
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
PRIMARY | |||
|
2235-90-7
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
PRIMARY | |||
|
GR181O3R32
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
PRIMARY | |||
|
8367
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
PRIMARY | |||
|
DTXSID1046764
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
PRIMARY | |||
|
PE 006
Created by
admin on Fri Dec 15 16:17:30 GMT 2023 , Edited by admin on Fri Dec 15 16:17:30 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
